NDA for Alzheimer’s Combined Drug Namzaric Approved by FDA

NDA for Alzheimer’s Combined Drug Namzaric Approved by FDA
Actavis and Adamas Pharmaceuticals Inc. announced that the US Food and Drug Administration has accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, for the treatment of moderate to severe Alzheimer’s Disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric, is also known as MDX-8704. In cases of known difficulty in

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Mrs James Harriss says:

    We are living on social security and can not afford the cost of the Namazaric. The doctor gave us a sample box , which we started July 21st. My husband is 90years old , and needs help. We would be thankful for help.

Leave a Comment

Your email address will not be published. Required fields are marked *